Seeking Alpha

The EMA grants Orphan Medicinal Product status to Verastem's (VSTM) small molecule inhibitor...

The EMA grants Orphan Medicinal Product status to Verastem's (VSTM) small molecule inhibitor VS-6063 for the treatment of mesothelioma. The designation gives the drug a leg up in terms of market exclusivity upon approval and opens the door for EMA assistance throughout clinical development. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|